The world's only dual-patient medication dispenser — from Finland
MoniDose builds smart, automatic medication dispensing for welfare regions, care homes, home care and assisted living. We are in advanced field testing in Finland and opening conversations with strategic investors about the next phase of growth.
Two products, one mission
MoniDose is already a multi-product company: the dispenser is in field testing and the eQMS platform is already on the market. Both share the same foundation — quality, regulatory rigour and patient safety.
MoniDose Dispenser
The world's only dual-patient smart medication dispenser
Smart, automatic medication dispensing for care homes, home care and assisted living. Being developed as a Class I medical device under EU MDR 2017/745.
- Dual-patient mode on a single device
- QR identification + locked tamper-resistant storage
- Four-role apps: nurse, resident, family, pharmacy
- Not yet registered — Fimea registration planned
MoniDoseQMS
Electronic quality management system for medical device companies
MoniDoseQMS is our own eQMS platform. We use it ourselves in development — and we offer it as a standalone SaaS product to other medical device manufacturers to meet MDR requirements.
- Document management + version control
- ISO 14971 risk management
- CAPA system + non-conformity handling
- Covers the full MDR lifecycle
From an investor perspective: MoniDoseQMS is already a standalone product on the market — proof that the team has built and shipped a certification-grade software platform. The dispenser is the next product launching from the same foundation.
Why now?
Four structural drivers converge — making smart medication dispensing a necessity, not an option.
An ageing population
The share of people over 65 is rising in Finland and across Europe. Care is shifting from institutions into the home — exactly where medication errors stack up.
Polypharmacy is increasing
More elderly patients take five or more prescription medications every day. Manual schedules overwhelm staff and create error risk.
Care workforce is constrained
Care homes and home care cannot scale manual medication dispensing further. The structural demand for automation is built in.
Regulation is tightening
EU MDR 2017/745 and national quality requirements favour companies that built the regulatory path from day one — not as an afterthought.
What we have built — and where we are now
Product family, regulatory path and quality system are in place — the next step is registration and commercial scale-up.
The world’s only dual-patient dispenser
One device serves two patients with separate schedules, alerts and logs. The product family also covers single-patient deployments for care units and homes.
A four-role platform
Distinct views for nurse, patient, family member and pharmacy. Alert routing, two-way video and automatic documentation tie everyday work into existing record systems.
A regulatory path built in
The device is being developed as a Class I medical device (with software) under EU MDR 2017/745 via the self-declaration route (Article 52(7)). The device is not yet registered — registration with Fimea is on the regulatory roadmap.
MoniDoseQMS for quality management
We use our own MoniDoseQMS platform to manage documentation, risk and CAPA processes. The same platform is also available as a standalone product at monidoseqms.com.
Advanced field testing underway
MoniDose is currently in advanced field testing with Finnish healthcare providers. The learnings inform product development and commercial readiness.
Security and privacy by design
We handle health data. Our website has been audited against the OWASP Top 10 (2021) framework, with 18 security controls verified. We hold our digital infrastructure to the same standard as our physical products.
What the product is designed to deliver
These are designed outcomes informed by field testing — not yet audited commercial results.
Designed time saving at a 5-patient load — around 55–77 hours per device per month.
The world’s only dual-patient mode — two separate schedules, alerts and logs in the same device.
Patient identification and tamper-resistant locked storage reduce error risk across the chain.
Where invested capital goes
Four pillars, one outcome: move the device from field testing into broad commercial use.
Finish product & regulatory
Move the device from field testing to MDR registration (Fimea), deepen integrations with patient record systems and build clinical evidence.
Team & commercialisation
Key hires in sales, customer success and regulatory affairs. From pilot units to repeatable deployments.
Geographic expansion
Finland → Nordics → selected European markets. One market at a time, on regulatory and distribution terms.
Quality & continued development
Expanding the MoniDoseQMS platform, post-market surveillance and next-generation device capabilities.
The investors we are looking for
Strategic partners
Players with deep understanding of healthcare, care services or pharmacy operations.
Long-term funds
Investors who understand the rhythm of a medical device growth curve — from registration to broad deployment.
Nordic & European reach
Partners who support sequenced expansion from Finland to the Nordics and selected European markets.
Investor inquiry
Tell us briefly about your background and what interests you. We treat all information confidentially and reply personally.